Introduction
The ErbB family of receptors is mutated or overexpressed in many solid tumors and aberrantly activated ErbB receptor signals have been associated with poor prognosis [1]. Among ErbB receptors, epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) have been implicated as important therapeutic targets for lung, breast, and gastric cancers. The first-generation EGFR tyrosine kinase inhibitors (TKIs) including gefitinib and erlotinib reversibly inhibit EGFR tyrosine kinase by competing with adenosine triphosphate [1]. These have shown clinical benefits for EGFR-mutant non-small cell lung cancer (NSCLC) with median progression-free survivals of 9 to 11 months; however, acquired resistance to these TKIs is inevitable [2]. Due to limited clinical success of first-generation EGFR TKI, second-generation and irreversible EGFR TKIs have been developed for targeting EGFR, HER2, and ErbB4 such as dacomitinib and afatinib [3]. These second-generation EGFR TKIs have shown favorable survival outcomes in lung adenocarcinoma with activating EGFR mutations [4-6].
Poziotinib (HM781-36B) is an irreversible pan-HER TKI, which targets EGFR, HER2, and ErbB4. Poziotinib shows good in vitro activities in EGFR or HER2 expressing various cancer cell lines including EGFR TKI–resistant lung cancer cells. Poziotinib effectively inhibited ErbB family kinases (IC50, 3.2, 2.2, 5.3, and 23.5 nM against EGFRwild-type, EGFRT790M/L858R, HER2, and HER4, respectively) [7]. In addition, HER2-amplified gastric cancer cells and breast cancer cells were sensitive to poziotinib alone (IC50, 1-4 nM and 1-9 nM, respectively) or poziotinib in combination with various chemotherapeutic agents [8,9].
Here, we conducted the first-in-human phase I studies of poziotinib to determine the maximum tolerated dose (MTD), pharmacokinetics, safety, and antitumor activity in patients with advanced solid tumors.
Materials and Methods
1. Patients
Eligible patients were ≥ 19 years with histologically or cytologically confirmed advanced solid tumor, Eastern Cooperative Oncology Group performance status ≤ 2; with previous chemotherapy, a life expectancy greater than 12 weeks; and adequate bone marrow (absolute neutrophil count ≥ 1,500/mm3, platelet ≥ 100,000/mm3, and hemoglobin ≥ 9.0 g/dL), renal (serum creatinine ≤ 1.5 mg/dL) and hepatic (serum transaminases ≤ 3× upper limit of normal and total bilirubin ≤ 2 mg/dL) functions. Patients who had undergone radiation therapy or surgery within 4 weeks prior to study were excluded. Patients were excluded if they had uncontrolled infection, ileus, metastasis to central nervous system, class III or IV heart failure or left ventricular ejection fraction < 40%, gastrointestinal malabsorption or difficulty in taking oral medication, or taken other investigational products within 30 days before screening.
2. Study design and treatment
We conducted two phase I, open label studies to determine the MTD for two different dosing schedules. In NCT0145571 (study A), poziotinib tablet was administered with water once daily on an intermittent basis (14-day on and 7-day off) schedule at multiple dose levels (0.5, 1, 2, 4, 8, 12, 16, 20, 24, and 32 mg) (n=55, study A), and in NCT01455584 (study B), poziotinib was given once daily in a continuous dosing fashion, at dose levels of 12, 18, and 24 mg and 16 mg with food in the fasting or fed state by period in a cross-over design (n=20, study B). In the dose escalation part for both studies, cohorts of three to six patients were treated at increasing doses of poziotinib to determine the MTD. A traditional 3+3 dose-escalation design was used with MTD defined as the dose where dose-limiting toxicities (DLTs) observed in one or more out of six patients in the first cycle. Once the MTD was identified, 12 patients were enrolled in the expansion part (study A, only). Food effect was conducted based on a 2×2 cross-over design (fasting-fed sequence versus fed-fasting sequence after randomization) once the recommended dose (RD) was determined (study B, only).
3. Pharmacokinetic analyses
In study A, serial blood and urine samples were collected on day 1 for up to 24 hours (just before administration, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours after dosing) and day 14 of cycle 1 up to 48 hours (just before administration, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, and 48 hours after dosing) (n=52). To assess the food effect on pharmacokinetic (PK) of poziotinib in study B, eigh additional patients were enrolled, and blood samples were taken on day 1 and day 8 up to 24 hours (just before administration, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours after dosing) on fasting or fed condition (n=8). Plasma samples were analyzed for poziotinib concentration at BioInfra Co., Ltd. (Suwon, Korea). The analytes were extracted from heparinized human plasma. The analytes were then separated and detected by validated ultra-performance liquid chromatography with tandem mass spectrometry [10]. Noncompartmental analysis for plasma concentration was performed using Phoenix WinNonlin Software ver. 6.3 (Pharsight, Mountain View, CA).
4. Efficacy and safety analyses
Adverse events (AEs) and treatment-emergent AEs (TEAEs) were evaluated using National Cancer Institute Common Terminology Criteria for Adverse Events ver. 3.0. DLTs were defined as grade ≥ 3 non-hematologic toxicities (except for alopecia), grade ≥ 3 diarrhea, nausea and vomiting despite maximal anti-diarrheal, anti-emetics medication, grade 4 neutropenia sustained for 7 days or more or febrile neutropenia, grade ≥ 3 neutropenic infection accompanying grade 4 neutropenia or grade 4 thrombocytopenia. Treatment response to poziotinib was evaluated every two cycles based on the Response Evaluation Criteria in Solid Tumors criteria (RECIST) ver. 1.0 [11]. Progression-free survival (PFS) was measured as the interval between poziotinib first dose administration and the date when disease progression by RECIST ver. 1.0 or death was first documented.
5. Biomarker and molecular analyses
Plasma or tumor samples in the expansion cohort (n=12, study A) and in the continuous and food effect cohort (n=20, study B) were collected for EGFR mutation on exons 18-21, KRAS mutation on exon 2, BRAF mutation on exon 15, and PIK3CA mutation on exons 9 and 20 using a peptide nucleic acid (PNA)-mediated clamping polymerase chain reaction (PCR) method (PANAGENE, Inc., Daejeon, Korea) [12]. Plasma hepatocyte growth factor (HGF) concentration was determined using quantitative sandwich enzyme immunoassay technique (Seoul Clinical Laboratories Co., Ltd., Yongin, Korea). Plasma and tumor samples derived from patients (n=14, studies A and B) with partial response (PR) or stable disease (SD) ≥ 12 weeks were examined for EGFR (EGFR/CEP7 probe, Abbott Laboratories, Des Plaines, IL), HER2 (HER2/CEP7 probe, Abbott Laboratories), HER3 (HER3/CEN12 probe, ZytoVision GmbH, Bremerhaven, Germany), or HER4 (HER4/2q11 probe, ZytoVision GmbH) amplification and EGFR or HER2 mutation (PNA-mediated clamping PCR or direct sequencing).
6. Ethical statement
These studies were conducted in compliance with the Declaration of Helsinki and following the International Conference on Harmonization Good Clinical Practice Guidelines. In addition, these studies were approved by the Institutional Review Board of each participating center. Written informed consents were obtained.
Results
1. Patients
A total of 75 patients were enrolled in both studies (55 in the intermittent schedule and 20 patients in the continuous dosing schedule, respectively). Study A included 43 patients in the dose escalation portion and 12 patients in the expansion cohort at the MTD. Study B included 12 patients in the dose escalation portion and eight patients in the food effect cohort. Nearly one-third of the patients (n=27) in both studies had a diagnosis of NSCLC and the majority of patients (65%) received fourth-line or above chemotherapeutic regimens (Table 1).
2. Safety profiles
All 75 patients were included in the safety analysis. Fifty-two patients (95%) in the intermittent schedule and 20 patients (100%) in the continuous schedule experienced at least one drug-related AE. The most common drug-related TEAEs were diarrhea, rash, stomatitis, pruritus, and anorexia (Table 2). DLTs in the intermittent dosing schedule were grade 3 diarrhea in five patients (one each at 12, 16, 24 mg levels, and two at 32 mg) in dose escalation part and grade 3 diarrhea in three patients, grade 3 nausea in one patient, and grade 3 mucosal inflammation in one patient in 24 mg expansion part (Table 3). DLTs in the continuous dosing schedule were grade 3 anorexia (one at 18 mg), grade 3 diarrhea with anorexia (one at 24 mg), and drug compliance as defined by actual dosage administered/dosage that should be administered ×100 < 80% due to grade 2 toxicities such as anorexia, rash, nausea, fatigue and diarrhea (one at 24 mg) (Table 3). The MTDs were determined as 24 mg/day in the intermittent dosing schedule and 18 mg/day in the continuous dosing schedule.
3. Efficacy
There were 51 evaluable patients by RECIST ver. 1.0 in the intermittent dosing schedule (study A) and out of those, eight patients (16%) achieved PR (breast cancer, n=4; NSCLC, n=2; and gastric and colorectal cancers, n=1, respectively) and 24 (47%) had SD (Fig. 1A). The disease control rate (DCR, PR+SD) was 63%. The median PFS was 12.0 weeks (95% confidence interval [CI], 7.4 to 16.5) for all patients and 13.4 weeks (95% CI, 11.5 to 18.9) in patients treated with at least 8 mg/day (n=39). All of the three patients (100%) receiving 8 mg/day developed a rash, a well-known AE related with inhibition of wild-type EGFR. Considering Ki-67–positive cells decreased after treatment with ≥ 8 mg poziotinib, the minimum effective dose for poziotinib was estimated to be 8 mg/day.
There were 19 evaluable patients in the continuous dosing schedule (study B). Four patients (21%) including two breast and one common bile duct cancers and one NSCLC achieved PR and six (32%) achieved SD; the DCR was 53% (Fig. 1B). The median PFS was 9.0 weeks (95% CI, 5.7 to 39.7). Among 27 NSCLC patients, 26 had received prior EGFR TKIs (first-generation EGFR TKIs, n=26; and second-generation EGFR TKIs, n=3). Three (11%) and 11 (41%) patients achieved PR and SD, respectively (Fig. 1C). The median PFS was 11.4 weeks (range, 5.6 to 17.4 weeks).
4. Pharmacokinetics
PK data for poziotinib was previously reported [10]. Briefly, dose-proportional pharmacokinetics profiles were observed in terms of Cmax and area under plasma concentration-time curve (AUC) in dose range of 0.5 to 24 mg on day 1. Absorption rate of poziotinib was moderate to high with a median Tmax between 0.6 and 4 hours and mean terminal half-lives ranged from 5.09 to 9.92 hours in day 1. PK parameters were similar between single (on day 1) and multiple oral doses (on day 14).
There was minimal difference in the geometric mean AUC values of poziotinib between dosing under fed conditions and dosing under fasting conditions. The geometric mean Cmax of poziotinib decreased approximately by 27% under fed conditions compared with fasting conditions. The median Tmax of poziotinib was delayed from 1.26 (0.95, 3.00) to 3.01 (1.00, 7.85) hours with food intake (S1 Table).
5. Molecular studies
Tissue (n=9) and plasma (n=12) samples in the expansion part of study A (intermittent dosing schedule) and plasma (n=9) samples in the continuous dosing schedule (study B) were collected for genetic studies. EGFR exon 19 deletion was observed in five NSCLC patients’ tissue samples, two of which harbored concomitant EGFRT790M mutation. Plasma or tumor samples showed EGFR exon 19 deletions (n=6), EGFRT790M mutation (n=5), EGFRL858R or EGFRL861Q mutation (n=2), and KRAS mutation (n=1). Molecular profiles, HGF concentrations and best response are described in S2 Table. Patients with PR (n=7) or SD ≥ 12 weeks (n=7) had HER2 amplification (n=7; breast cancer, 5; and stomach cancer, 2) and EGFR amplification (n=1, squamous cell lung cancer) (S3 Table).
Discussion
Poziotinib is an irreversible pan-HER TKI that has shown a manageable safety profile in our first-in-human studies, very similar to those seen with other TKIs. The MTDs were determined as 24 mg/day in the intermittent dosing schedule 2 (study A) and 18 mg/day in study B (continuous dosing) with a RD of 16 mg once daily. A linear increase in poziotinib exposure with increasing doses was observed in PK analyses. The best overall responses were 15.7% in study A and 21.1% in study B, respectively. In addition, encouraging efficacy was observed in EGFR-mutant NSCLC and HER2-amplified breast or stomach cancers. The most common AEs observed were diarrhea, skin rash, stomatitis, and pruritus and DLT was diarrhea, in line with other irreversible pan-HER TKIs [13,14].
To evaluate the PK profile, PK and plasma assessments were performed on days 1 and 14 of the cycle 1 from 52 of a total of 55 patients in study A. The exposure to poziotinib increased generally dose-proportionally at doses up to 24 mg/day (i.e., MTD) and these data indicate that human PK of poziotinib showed dose dependency on oral absorption. In addition, the PK parameters relevant to poziotinib exposure at steady state (on day 14) were similar to those obtained following a single dose (on day 1) suggesting no accumulation of poziotinib after multiple administrations. In terms of food effect, PK data showed delay in Tmax and decreased in Cmax of poziotinib with food, but there were no significant differences in the exposure (AUC). Therefore, the anticancer activity of poziotinib is not altered by food ingestion.
In the present studies, EGFR, HER2, KRAS, BRAF, PIK3CA mutations, EGFR and HER2 amplifications, as well as plasma HGF concentrations were analyzed in an exploratory manner. In terms of the best overall response by genetic status, one NSCLC patient with EGFR exon 19 deletion mutation achieved SD and two NSCLC patients with EGFR exon 19 deletion and T790M mutation showed SD and PR, respectively. Although two NSCLC patients progressed despite the presence of EGFR activating mutations, this might be due to unknownresistance mechanisms associated with EGFR TKIs, considering that the tumor sample was collected after previous treatment with EGFR TKIs. Taken together, after treatment with poziotinib, SD or PR was confirmed in three of six NSCLC patients with EGFR exon 19 deletion mutation or concomitant EGFR exon 19 deletion and T790M mutation. Poziotinib showed encouraging efficacy in EGFR-mutant NSCLC after failure of prior EGFR TKIs (PR, 12.5%) unlike other pan-HER inhibitors [13,14]. In addition, half of patients with clinical benefit (PR or SD ≥ 12 weeks) had HER2 amplification, mostly observed in patients with breast or stomach cancers. These results have led to the initiation of other poziotinib trials in various solid tumors, including EGFR-mutant lung adenocarcinoma as a first-line (NCT01819428) and as a second-line after failure to first-generation EGFR TKIs (NCT01718847), as well as in HER2-overexpressed breast and gastric cancers (NCT02418689, NCT02659514 and NCT01746771, respectively).
In conclusion, poziotinib is a promising irreversible pan-HER inhibitor against EGFR-mutant NSCLC as well as HER2-overexpressing breast and gastric cancers and was generally tolerated in heavily pre-treated cancer patients.
PDF Links
PubReader
ePub Link
XML Download
Full text via DOI
Download Citation 
CrossRef TDM
Supplement1
Print 
